Anna Passarelli
National Cancer Institute, Naples
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anna Passarelli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07522697 · Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4National Cancer Institute, Naples · not yet recruiting · Endometrial Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:29 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.Ann Oncol · 202437 citationsRCR 4.1
- 3 citationsRCR 0.7
- [Controlled clinical trial of 5 antianginal treatments].G Ital Cardiol · 19782 citationsRCR 0.1
- Effect of mental practice on surgical trainees' ability to describe an ulnar shortening osteotomy after video observation: An experimental study.Hand Surg Rehabil · 20250 citationsRCR 0.0